Medtronic Fishes For Urology Growth, Lands TUNA BPH Device With VidaMed

Medtronic's $326 mil. acquisition of VidaMed is expected to close in January 2002, just as Medicare reimbursement for the firm's transurethral needle ablation (TUNA) system for benign prostatic hyperplasia (BPH) increases from $2,455 per procedure to $3,043